Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Jun;61(6):821-8.
doi: 10.1136/gutjnl-2011-301454. Epub 2011 Dec 9.

A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia

Kei Matsueda  1 , Michio Hongo, Jan Tack, Youichi Saito, Hiroki Kato
Affiliations
Clinical Trial

A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia

Kei Matsueda et al. Gut. 2012 Jun.

Abstract

Objective: To determine the efficacy of acotiamide, an acetylcholinesterase inhibitor, in patients with functional dyspepsia (FD) in a 4-week trial.

Methods: A multicentre, randomised, placebo-controlled, parallel-group, phase III trial was carried out, in which patients with FD received 100 mg of acotiamide or placebo three times a day for 4 weeks, with 4 weeks post-treatment follow-up. The primary efficacy end points were global assessment of overall treatment efficacy (OTE) and elimination rate of all three meal-related symptoms (postprandial fullness, upper abdominal bloating and early satiation), as derived from daily diaries. Secondary efficacy end points were individual symptom scores and quality of life. Adverse events were monitored.

Results: 52.2% of those receiving acotiamide and 34.8% in the placebo group (p<0.001) were classified as responders according to a global assessment of OTE. Over 4 weeks, the elimination rate for all three meal-related symptoms was 15.3% among patients receiving acotiamide compared with 9.0% in the placebo group (p=0.004). The significant benefit of acotiamide over placebo in OTE and elimination rate was maintained during the 4 week post-treatment follow-up. All other secondary efficacy end points, including quality of life, were significantly improved with 100 mg of acotiamide as compared with placebo. The number needed to treat was 6 for OTE and 16 for symptom elimination rate. The incidence of adverse events was similar between the acotiamide group and placebo group and no significant cardiovascular effects due to treatment were seen.

Conclusions: Over 4 weeks, acotiamide significantly improved symptom severity and eliminated meal-related symptoms in patients with FD.

Trial registration number: http://ClinicalTrials.gov number, NCT00761358.

PubMed Disclaimer

Conflict of interest statement

Competing interests: KM has provided scientific advice to Astellas, Zeria, Ajinomoto, Abbott. MH has provided scientific advice to Astellas, Zeria, Takeda, Eisai, AstraZeneca, Sucampo. JT has provided scientific advice to Addex Pharma, Almirall, Aryx, AstraZeneca, Danone, Given, Ipsen, Menarini, Movetis, Norgine, Novartis, Nycomed, Ocera, Rose Pharma, SK Life Sciences, Smartpill, Sucampo, Theravance, Tranzyme, Xenoport and Zeria. YS and HK are employees of Zeria.

Figures

Figure 1
Figure 1
Trial design. Daily dose: three times a day before meal.
Figure 2
Figure 2
Summary of patient flow. FAS, full analysis set.
Figure 3
Figure 3
Weekly improvement rate in overall treatment efficacy. ***p<0.005 compared with placebo. FW, follow-up week after treatment; W, week.
Figure 4
Figure 4
Elimination rate for all three symptoms. *p<0.05 compared with placebo. ***p<0.005 compared with placebo. FW, follow-up week after treatment; W, week.
See this image and copyright information in PMC

Comment in

References

    1. Drossman DA, Corazziari E, Delvaux M, et al. Rome III: The Functional Gastrointestinal Disorders. 3rd edn McLean, VA: Degnon Associates, Inc., 2006
    1. Stanghellini V. Three-Month Prevalence Rates of Gastrointestinal Symptoms and the Influence of Demographic Factors: Results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999;231:20–8 - PubMed
    1. Kawamura A, Adachi K, Takashima T, et al. Prevalence of functional dyspepsia and its relationship with Helicobacter pylori infection in a Japanese population. J Gastroenterol Hepatol 2001;16:384–8 - PubMed
    1. Okumura T, Tanno S, Ohhira M, et al. Prevalence of functional dyspepsia in an outpatient clinic with primary care physicians in Japan. J Gastroenterol 2010;45:187–94 - PubMed
    1. Nakajima S. The spectra of functional gastrointestinal disorders (FGID) in a Japanese hospital outpatient department according to the ROME II Integrative Questionnaire. J Gastroenterol Hepatol 2008;23(Suppl 2):S186–92 - PubMed

Publication types

Associated data